Table 2.
Anti-proliferative activity (IC 50 values) of D-allose alone and in combination with platinum analogs and/or SB202190
| D-allose + Platinum | D-allose + 20 μM SB202190 (mM) | D-allose + 20 μM SB202190 + Platinum | ||||||
|---|---|---|---|---|---|---|---|---|
| Cell line | D-allose (mM) | Platinum (μM) | D-allose (mM) | Platinum (μM) | CI at IC50 | D-allose (mM) | Platinum (μM) | |
| MIA PaCa-2 | 53.25 | 3.37 | 4.16 | 0.95 | 0.696 | 3.18 | 1.98 | 0.99 |
| BxPC-3 | >100 | 28.13 | 43.3 | 21.65 | 0.787 | 4.09 | 8.75 | 4.38 |
| ASPC-1 | >100 | >50 | >100 | >50 | n/c | 74.11 | >100 | >50 |
| OVCAR-3 | >100 | 6.93 | 15.84 | 7.92 | 1.171 | >100 | 51.7 | 25.85 |
| HEY | >100 | 32.90 | 52.68 | 26.34 | 1.002 | 94.17 | 53.01 | 26.5 |
| SK-OV-3 | >100 | 11.53 | 18.55 | 9.27 | 0.857 | 10.82 | 9.74 | 4.87 |
IC50 values represent the level of drug that inhibited cell growth by 50% following 48 hours of treatment. Combination index (CI) values are defined as: <0.1 = very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = moderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive, 1.1-1.45 slight to moderate antagonism.